Timothy P Hughes

Summary

Affiliation: South Australia
Country: Australia

Publications

  1. doi request reprint Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction
    Timothy P Hughes
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide 5000, South Australia, Australia
    Clin Lymphoma Myeloma 9:S266-71. 2009
  2. doi request reprint Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
    Laura N Eadie
    Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
    Leuk Lymphoma 54:569-78. 2013
  3. ncbi request reprint Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo
    Cara K Fraser
    Hanson Institute, Adelaide, The University of South Australia, South Australia, Australia
    Cancer Biol Ther 10:715-27. 2010
  4. doi request reprint Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo
    Cara K Fraser
    Hanson Institute, South Australia, Australia
    Exp Hematol 37:1435-44. 2009
  5. doi request reprint The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
    Jane R Engler
    Division of Haematology, SA Pathology RAH Campus, Adelaide, Australia
    Blood 116:2776-8. 2010
  6. doi request reprint Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
    Stephen Fitter
    Myeloma Research Laboratory, Department of Hematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, G P O Box 14, Adelaide, South Australia 5000, Australia
    J Clin Endocrinol Metab 95:3763-7. 2010
  7. doi request reprint Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
    Timothy P Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 112:3965-73. 2008
  8. doi request reprint Dysregulation of bone remodeling by imatinib mesylate
    Kate Vandyke
    Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 115:766-74. 2010
  9. ncbi request reprint Imatinib inhibits the functional capacity of cultured human monocytes
    Andrea L Dewar
    Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    Immunol Cell Biol 83:48-56. 2005
  10. doi request reprint Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
    Stephen J Blake
    Department of Haematology, SA Pathology, RAH Campus, Adelaide, South Australia, Australia
    Exp Hematol 40:612-21.e6. 2012

Collaborators

Detail Information

Publications23

  1. doi request reprint Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction
    Timothy P Hughes
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide 5000, South Australia, Australia
    Clin Lymphoma Myeloma 9:S266-71. 2009
    ....
  2. doi request reprint Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
    Laura N Eadie
    Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
    Leuk Lymphoma 54:569-78. 2013
    ..Imatinib and nilotinib appear to be transported by ABCB1 but do not interact strongly with ABCG2. Furthermore, ABCB1 efflux of nilotinib may be concentration-dependent with transport occurring at clinically relevant concentrations...
  3. ncbi request reprint Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo
    Cara K Fraser
    Hanson Institute, Adelaide, The University of South Australia, South Australia, Australia
    Cancer Biol Ther 10:715-27. 2010
    ....
  4. doi request reprint Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo
    Cara K Fraser
    Hanson Institute, South Australia, Australia
    Exp Hematol 37:1435-44. 2009
    ..The purpose of this study was to evaluate the effect of dasatinib on cytokine secretion in response to toll-like receptor (TLR) stimulation...
  5. doi request reprint The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
    Jane R Engler
    Division of Haematology, SA Pathology RAH Campus, Adelaide, Australia
    Blood 116:2776-8. 2010
    ..Therefore kinase inhibition in these mature cells, and not the CD34(+) cells, may be the key determinant of response in CML...
  6. doi request reprint Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
    Stephen Fitter
    Myeloma Research Laboratory, Department of Hematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, G P O Box 14, Adelaide, South Australia 5000, Australia
    J Clin Endocrinol Metab 95:3763-7. 2010
    ..The mechanism(s) by which imatinib improves glycemic control in chronic myeloid leukemia (CML) patients with type 2 diabetes remains unclear...
  7. doi request reprint Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
    Timothy P Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 112:3965-73. 2008
    ..Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493...
  8. doi request reprint Dysregulation of bone remodeling by imatinib mesylate
    Kate Vandyke
    Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 115:766-74. 2010
    ..The potential application of imatinib in the treatment of cancer-induced osteolysis will also be discussed...
  9. ncbi request reprint Imatinib inhibits the functional capacity of cultured human monocytes
    Andrea L Dewar
    Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    Immunol Cell Biol 83:48-56. 2005
    ....
  10. doi request reprint Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
    Stephen J Blake
    Department of Haematology, SA Pathology, RAH Campus, Adelaide, South Australia, Australia
    Exp Hematol 40:612-21.e6. 2012
    ..Furthermore, the technique to evaluate drug interactions is novel, and applicable to study any interaction affecting proliferation...
  11. ncbi request reprint Inhibition of c-fms by imatinib: expanding the spectrum of treatment
    Andrea L Dewar
    Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
    Cell Cycle 4:851-3. 2005
    ..We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma...
  12. doi request reprint Mutational analysis in chronic myeloid leukemia: when and what to do?
    Susan Branford
    Department of Molecular Pathology, SA Pathology, University of Adelaide, Adelaide, South Australia, Australia
    Curr Opin Hematol 18:111-6. 2011
    ..More sensitive mutation techniques that focus on the detection of a limited number of specific mutations may be beneficial, but are yet to prove their clinical utility for the early detection of relapse in routine practice...
  13. ncbi request reprint Imatinib as a potential antiresorptive therapy for bone disease
    Andrea L Dewar
    Division of Haematology, Institute of Medical and Veterinary Science, Frome Rd, Adelaide 5000, Australia
    Blood 107:4334-7. 2006
    ..These results suggest that imatinib may have therapeutic value as an antiosteolytic agent in diseases such as osteoporosis, metastatic bone disease, and multiple myeloma...
  14. doi request reprint Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease
    David M Ross
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
    Clin Chem 54:1568-71. 2008
    ..More sensitive PCR methods are required to assess whether these patients have a long-term continuing decline in residual disease...
  15. doi request reprint Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
    Cara K Fraser
    Experimental Therapeutics Laboratory, Hanson Institute, South Australia, Australia
    Exp Hematol 37:256-65. 2009
    ..The purpose of this study was to evaluate the inhibitory action of dasatinib on antigen-specific CD8(+) and CD4(+) T-cell function, as well as natural killer (NK) cell cytotoxicity...
  16. ncbi request reprint Strategies for the treatment of imatinib-resistant chronic myeloid leukemia
    Chi hung Hui
    Hematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Frome Road, Adelaide SA 5000, Australia
    Clin Adv Hematol Oncol 1:538-45, 559. 2003
    ..The useful laboratory tests to study imatinib resistance and a current Australian CML study employing imatinib dose intensification and sequential combination therapy for newly diagnosed patients are also outlined...
  17. ncbi request reprint Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications
    Devendra K Hiwase
    Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Adelaide, South Australia, Australia
    Clin Cancer Res 14:3881-8. 2008
    ..The relevance of OCT-1 activity and efflux pumps in determining intracellular uptake and retention (IUR) of dasatinib was assessed...
  18. ncbi request reprint Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
    Andrea L Dewar
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    Blood 105:3127-32. 2005
    ..Imatinib should now be assessed for activity in diseases where c-fms activation is implicated, including breast and ovarian cancer and inflammatory conditions...
  19. ncbi request reprint Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene
    Susan Branford
    Division of Molecular Pathology, Institute of Medical and Veterinary Science, Box 14, Rundle Mall, Adelaide, SA 5000, Australia
    Br J Haematol 117:875-7. 2002
    ..We conclude that the BCR intronic polymorphism is associated with activation of a cryptic branchpoint resulting in reduced efficiency of RNA splicing and exon 14 (b3) skipping in BCR and BCR-ABL...
  20. ncbi request reprint How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
    David M Ross
    Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA, Australia
    Leuk Lymphoma 49:1230-1. 2008
  21. doi request reprint Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    Deborah L White
    Division of Haematology, SA Pathology IMVS RAH Campus, Frome Road, Adelaide, South Australia, Australia
    Curr Hematol Malig Rep 4:59-65. 2009
    ..In the future, assays that directly assess the efficacy of the protein-drug interaction, taking into account factors intrinsic to the patient and the amount of drug freely available in the plasma, are likely to be of greater value...
  22. ncbi request reprint High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
    Susan Branford
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 99:3472-5. 2002
    ..Certain mutations may respond to higher doses of imatinib, whereas other mutations may mandate switching to another therapeutic strategy...
  23. ncbi request reprint Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench
    Chi hung Hui
    Haematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Leuk Lymphoma 47:1721-3. 2006